Cost-effectiveness of lenvatinib plus pembrolizumab as the second-line treatment for advanced endometrial carcinoma.

Saved in:
Bibliographic Details
Title: Cost-effectiveness of lenvatinib plus pembrolizumab as the second-line treatment for advanced endometrial carcinoma.
Authors: Chiang ST; Oncology Wards & Phase I Center, Department of Nursing, National Taiwan University Hospital, Taipei, Taiwan., Chueh CH; Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, San Diego, CA, USA., Wen YW; Department of Biomedical Science, College of Medicine, Chang Gung University, Taoyuan, Taiwan., Chiang SC; Department of Pharmacy, College of Pharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan.; The Center of Advanced Pharmacy Education, Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan., Li WH; Gynecologic Robotic and Minimally Invasive Surgery Center, Shin Kong Wu Ho Su Memorial Hospital, Taipei, Taiwan. liwaihou@yahoo.com.tw., Tsai YW; Department of Pharmacy, College of Pharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan. ywtsai@nycu.edu.tw.; Institute of Health and Welfare Policy, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. ywtsai@nycu.edu.tw.; Medical AI Development Center, Taipei Veterans General Hospital, Taipei, Taiwan. ywtsai@nycu.edu.tw.
Source: Cost effectiveness and resource allocation : C/E [Cost Eff Resour Alloc] 2026 Jan 14; Vol. 24 (1). Date of Electronic Publication: 2026 Jan 14.
Publication Type: Journal Article
Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 101170476 Publication Model: Electronic Cited Medium: Print ISSN: 1478-7547 (Print) Linking ISSN: 14787547 NLM ISO Abbreviation: Cost Eff Resour Alloc Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1478-7547
DOI:10.1186/s12962-025-00711-y